Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069543" target="_blank" >RIV/00216224:14110/13:00069543 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/13:43907542 RIV/61989592:15110/13:33144638 RIV/65269705:_____/13:#0002083 RIV/00179906:_____/13:10145985 a 4 dalších

Výsledek na webu

<a href="http://dx.doi.org/10.1002/ajh.23508" target="_blank" >http://dx.doi.org/10.1002/ajh.23508</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.23508" target="_blank" >10.1002/ajh.23508</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

Popis výsledku v původním jazyce

Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months.The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts&gt;10% (P=0.005).

Název v anglickém jazyce

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

Popis výsledku anglicky

Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months.The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts&gt;10% (P=0.005).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Hematology

ISSN

0361-8609

e-ISSN

—

Svazek periodika

88

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

790-797

Kód UT WoS článku

000323313500013

EID výsledku v databázi Scopus

—